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Summary
QUESTIONS UNDER STUDY: The optimal strategy of
anti-infectious prophylaxis in patients with acute leuk-
aemia undergoing intensive chemotherapy remains a mat-
ter of debate. We assessed the impact of primary prophy-
laxis with posaconazole and levofloxacin on the incidence
of invasive fungal infections (IFI) and bacteraemia.
METHODS: A retrospective single-centre study including
two groups of adult patients with AML receiving intensive
chemotherapy. Group one without anti-infective prophy-
laxis (September 2008 – February 2010), and group two
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with anti-infective prophyalaxis (March 2010 – April
2011). The primary end-point was IFI according to the
EORTC/MSG 2008 definitions and bacteraemia.
RESULTS: Baseline characteristics were similar in the
non-prophylaxis (n = 43 patients; 99 chemotherapy cycles)
and the prophylaxis (n = 45; 104 chemotherapy cycles)
group. IFI were significantly reduced in the prophylaxis
group (55.3% vs. 88.9%; p = 0.0032) and there was a trend
of the projected IFI-free survival at 100 days to be in-
creased (50.1% vs. 25%; p = 0.0526). One-hundred day
overall survival (84.4% and 88.4%, p = 0.35) and 2-year
overall survival (64.4% and 58.1%; p = 0.64) were unaf-
fected. No difference in the occurrence of bacteraemia was
observed (32.3% vs. 34.6%; p = 0.8). A total of two (3.6%)
patients in the non-prophylaxis and three (6.7%) in the pro-
phylaxis group died due to IFI, and two (3.6%) in the non-
prophylaxis and none in the prophylaxis group patients had
to stop leukaemia treatment due to IFI.
CONCLUSIONS: The anti-infective prophylaxis with
posaconazole and levofloxacin resulted in a significant re-
duction of ‘possible’ IFI with a number-needed to treat to
prevent one IFI of only 3 but did not result in a reduction
of the incidence of bacteraemia.
Key words: acute myeloid leukaemia; prophylaxis;
infection; posaconazole; levofloxacin
Introduction
Supportive therapy for patients with acute myeloid leuk-
aemia (AML) and high-risk myelodysplastic syndrome
(MDS) undergoing intensive chemotherapy has improved
significantly during the last decades [1]. However, infec-
tions remain a major cause of morbidity and mortality
among this severely immunosuppressed patient population.
Without anti-infective prophylaxis, bacteraemia occurs in
up to 34% and invasive fungal infections (IFI) in up to
51.7% of all patients undergoing intensive chemotherapy
[2–7]. IFI have high-rates of morbidity and mortality and
can require prolonged antifungal treatment [8].
Swiss Medical Weekly · PDF of the online version · www.smw.ch Page 1 of 11
Different strategies have been developed to reduce the risk
of infections, especially IFI: (i) the empirical approach re-
lies on clinical parameters such as the presence of per-
sistent fever despite use of broad-spectrum antibiotics to
trigger antifungal therapy; (ii) the pre-emptive strategy is
based on standardised screening tests such as periodical
computed tomography (CT) scans, fungal polymerase
chain reaction (PCR), and galactomannan serum measure-
ments as well as bronchoalveolar lavage to guide anti-
fungal treatment; (iii) the prophylactic approach with the
administration of anti-infective chemotherapeutics in all
patients from the beginning of chemotherapy [9–13]. Each
of these approaches has distinct advantages and weak-
nesses: The empirical treatment does not prevent infection
and is known to result in overtreatment. The pre-emptive
strategy can delay the diagnosis, under-diagnose infections,
and can lead to an excess in morbidity and mortality. On
the other hand, the prophylactic approach raises concerns
about the emergence of chemo-resistant pathogens and as-
sociated costs [10, 14].
The optimal anti-infective strategy depends on many
factors such as the local incidence of infections, local mi-
crobial resistance pattern, quality and availability of
screening methods, structural characteristics of the facility
(e.g. high efficiency particulate air filtration), as well as
financial aspects.
At the University Hospital of Zurich an empirical approach
was traditionally followed to guide anti-microbial therapy
in patients with haematological malignancies. The bacterial
resistance pattern in this institution is still of relatively little
concern. Data from our microbiological surveillance data-
base showed that in 2008 28% of all Escherichia coli isol-
ates were resistant to ciprofloxacine, the extended-spec-
trum beta-lactamase (ESBL) rate among E.coli and Kleb-
siella pneumoniae was 10%, and approximately 4% of all
S.aureus isolates were identified as methicillin-resistant
Staphylococcus aureus (MRSA). Vancomycin-resistent En-
terococci are very uncommon. Importantly, a resistance
analysis from 2009 restricted to the leukaemia ward, re-
vealed a 100% susceptibility to ciprofloxacine for all gram-
negative isolates from positive blood cultures (n = 17).
However, the rate of possible IFI in our haematologic pa-
tient population seemed to exceed the level that would be
expected from the literature [3, 8]. Thus, considering our
local infection and resistance pattern, in March 2010 we
implemented a prophylactic anti-fungal strategy with posa-
conazole, and a prophylactic anti-bacterial approach with
levofloxacin. The change of our strategy was based on
the known efficacy of levofloxacine and posaconazole in
this setting, and was in line with current international re-
commendations (e.g. European Conference on Infections in
Leukaemia, ECIL) [2, 11, 15, 16]. Simultaneously, dexa-
methasone was introduced to prevent chemotherapy-in-
duced nausea and possibly reduce cytarabine-induced skin
toxicity. Here, we analyse the outcome with respect to IFI
and bacteraemia before and after implementation of this
new standard.
Methods
Study population and protocol
This retrospective single-centre study was performed in the
leukaemia ward and the haematopoietic stem cell trans-
plantation unit of the University Hospital Zurich. Patients
were included between September 1st 2008 and April 30th
2011. Two patient groups were analysed, one prior to ini-
tiation of the anti-infective prophylaxis in March 2010
(‘non-prophylaxis’) and one after its introduction (‘pro-
phylaxis’), respectively. The end of follow up was May
31st 2013. Patients were eligible if they were older than
18 years and received intensive chemotherapy for AML,
acute promyelocytic leukaemia (APL) or high-risk MDS
(IPSS >1.5). A total of 100 patients were screened, and
12 patients with chemotherapy cycles during both treat-
ment periods were excluded. Therefore, 88 patients were
included in the final analysis. Patients with AML and MDS
were treated according to the standard arm of the HOVON
42 protocol unless they participated in the HOVON 92
trial (from 09th of October 2009 until 18th of December
2009), or the HOVON 102 trial (starting from 14th October
2010) [17]. All trials were registered at the HOVON Data
Centre. Treatment protocols are available online (ht-
tp://www.hovon.nl). Patients with APL were treated ac-
cording to the APL2000 study (NCT00591526) until Janu-
ary 2010 and according to the APL2006 protocol
(NCT00378365) starting from February 2010. All these tri-
als were approved by the local Ethical Committee (Kan-
tonale Ethikkomission Zürich) and informed consent was
provided prior to inclusion. The local Ethical Committee
(Kantonale Ethikkomission Zürich) also approved the
present study and waived the requirement for written in-
formed consent due to its retrospective character.
Anti-infective prophylaxis
We did not use anti-bacterial or anti-fungal prophylaxis un-
til March 2010. In March 2010, we introduced an anti-
infective chemoprophylaxis scheme in combination with
an antiemetic prophylaxis with dexamethasone for all pa-
tients undergoing intensive chemotherapy. Anti-fungal che-
moprophylaxis consisted of oral amphotericine B (200 mg
QID) during chemotherapy and oral posaconazole (200 mg
TID) after completion of chemotherapy and until neut-
rophil recovery, defined as a sustained neutrophil count
>0.5 G/l or until therapeutic antifungal therapy was started.
No intravenous substitution for the anti-fungal prophylaxis
was provided if the oral formula was not tolerated and no
posaconazole dose adaption was performed in the case of
low serum concentrations. Anti-bacterial prophylaxis with
levofloxacin (500 mg OD) was given from the start of ther-
apy until neutrophil recovery or until intravenous antibiotic
treatment was needed, whatever occurred first. Antiemet-
ic prophylaxis and prophylaxis against cytarabine-induced
skin toxicity were intensified by adding dexamethasone (8
mg BID) during cytarabine-containing chemotherapy. Pro-
phylaxis against Pneumocystis jirovecii infection was star-
ted in all chemotherapy cycles containing dexamethasone
prophylaxis, and consisted of trimethoprime/sulfameth-
oxazole 800/160 mg three times a week. Anti-fungal pro-
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phylaxis was not routinely used during or after allogeneic
stem cell transplantation throughout the study period.
Anti-infective treatment
The empirical approach to treatment of patients with neut-
ropenic fever remained unchanged throughout the whole
study period: Blood cultures were taken and a broad-spec-
trum intravenous antibiotic therapy was started when fever
occurred. Fever was defined as a core temperature of >38.4
°C once or >38.0 °C twice, when measured by a tympanic
thermometer. Initial empirical antibacterial treatment con-
sisted of cefepime 2 g TID or tazobactam/piperacillin 4.5 g
TID, the latter being used if an abdominal focus was sus-
pected. A low-dose chest CT exam was performed and an
empirical antifungal treatment with intravenous amphoteri-
cine B-deoxycolate (1 mg/ kg body weight by continuous
infusion over 24 hours) was started if fever persisted for
more than 48 to 72 hours after initiation of the intravenous
antibiotic or if fungal infection of other sites was suspec-
ted (sinus, skin, hepatosplenic) [18]. Anti-fungal therapy
could be withheld according to the treating physicians’ dis-
cretion. No systematic screening for fungal infections using
serological essays (e.g. galactomannan) or anti-fungal-PCR
was employed and bronchoalveolar lavage or transthoracic
puncture of suspected fungal lesions were performed rarely
and only in highly-selected cases (e.g. therapy-refractory
fungal infections).
Facility
The leukaemia ward is situated in a historical building
(built in the middle of last century) with standard ventil-
ation. In contrast, the haematopoietic stem cell transplant-
ation ward was built within the structure in 1995 and is
equipped with high efficiency particulate air filtration and
positive air pressure. Construction work was ongoing in
some areas of the hospital throughout the observation peri-
od but did not directly affect the haematologic units. Most
AML patients were treated on the leukaemia ward and not
on the stem cell transplantation ward. Exceptions were due
to a shortage of hospital beds or organisational reasons.
Cycles of treatment on the transplantation ward are indic-
ated separately.
Local fungus surveillance programme
Our local surveillance programme consists of sporadic en-
vironmental air sampling for quantitative and qualitative
identification of filamentous fungi.
Measurements and definitions
Therapy cycles lasted from the first day of chemotherapy
until neutrophil recovery (absolute neutrophil count (ANC)
>0.5 G/L for 3 consecutive days). Aplasia time lasted from
the first day of an ANC <0.5 G/l until ANC recovery >0.5
G/l.
Risk assessment of AML and MDS were made according
to the HOVON 102 protocol, the APL2000/2006 protocols,
and the IPSS score, respectively. Diagnosis was made ac-
cording to the WHO 2008 Classification of Tumours of
Haematopoietic and Lymphoid Tissues [19].
Primary end points: Total number of fungal infections and
bacteraemias per therapy cycle were defined as the primary
end-points. Patients with IFI at diagnosis were excluded
from the analysis and the rate of fungal infections was ex-
pressed in proportion to patients at risk. Patients with bac-
terial infections at the beginning of a chemotherapy cycle
were excluded from the analysis and the rate of proven bac-
teraemia was expressed in proportion to cycle numbers.
The radiological presence of IFI was assessed by two in-
dependent radiologists who were blinded for the patient’s
clinical data. The radiological diagnosis of IFI required at
least one of the following 3 signs on CT: (i) Dense, well-
circumscribed lesions(s) with or without a halo sign, (ii)
air-crescent sign, (iii) cavitation. Discordant interpretations
were resolved by consensus in a second readout. Invasive
fungal infections were then classified as ‘possible’, ‘prob-
able’ or ‘proven’ according to the EORTC/MSG criteria
[20].
Secondary end-points were the overall survival at 100 days
and 2 years, time from initiation of chemotherapy to onset
of IFI, use of intravenous and oral antifungal and antibac-
terial therapy, and total duration of anti-fungal and anti-
bacterial medication defined as the sum of prophylactic
and therapeutic anti-infective therapy days. Additionally,
the fever days, and the time in the intensive care unit per
therapy cycle as well as the proportion of therapy cycles
complicated by antiviral treatment, the occurrence of
cytarabine-related skin toxicity, and the incidence of neut-
ropenic enterocolitis were assessed.
Statistical analysis
Baseline characteristics are displayed as frequencies and
percentages for categorical data and as means (standard de-
viation) for continuous data. Since patients typically had
more than one therapy cycle, the correlation between
cycles for the same patient has to be taken into account
when comparing cycle-specific variables between prophy-
laxis and non-prophylaxis periods. To account for this de-
pendency, generalised estimation equations (GEE) models
with each patient considered as a separate cluster were ap-
plied to test for differences. For each variable, an unstruc-
tured correlation matrix was assumed in a Poisson and lo-
gistic GEE for count and binary variables, respectively.
Patient-specific differences in IFI occurrence after the first
and last cycle were compared between the prophylaxis and
non-prophylaxis groups using a chi-square test. The time-
to-IFI was defined as the time between initiation of chemo-
therapy and the onset of IFI. If a patient did not develop
IFI, he or she was censored at the end of the observation
period (May 31st 2013) or at date of death. Survival func-
tions were estimated using the Kaplan-Meier estimate and
were compared between the prophylaxis and non-prophy-
laxis group using a log-rank test. Survival at 100-days and
two-years was compared using logistic regression. Mul-
tivariate analysis for the occurrence of IFI per therapy cycle
was performed using mixed effects logistic regression with
a random intercept for each patient. Correction for multiple
testing in these exploratory analyses was not performed.
All tests were performed at a significance level of α = 0.05
and confidence intervals were computed at a confidence
level of 95%. Statistical analysis was conducted using R
software [21].
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Results
Baseline characteristics
The study comprised 88 patients receiving a total of 203
therapy cycles. Baseline characteristics were equally dis-
tributed among the patients in the non-prophylaxis and the
prophylaxis periods with the exception of chemotherapy
cycles on the transplantation ward and duration of aplasia
as shown in table 1 and discussed below. The majority of
patients was treated for acute myeloid leukaemia (AML)
(n = 80, 90.9%), the remaining patients were diagnosed
with acute promyelocytic leukaemia (APL) (n = 7; 8%), or
MDS (refractory anaemia with excess blasts) (n = 1; 1.1%).
When applying the SAKK/HOVON 102 risk stratification
scheme for AML, 30 (37.5%) patients were stratified in the
‘good risk’, 12 (15%) in the ‘intermediate risk’, 28 (35%)
in the ‘poor risk’, and 10 (12.5%) in the ‘very poor risk’
Figure 1
Invasive fungal infections and fungal-free survival.
(A) Patients with invasive fungal infection (IFI) after first cycle (non-
prophylaxis 65.8% vs. prophylaxis 33.3%; p = 0.0088) and after the
last cycle of chemotherapy (non-prophylaxis 88.9% vs. prophylaxis
53.9%; p = 0.0032), respectively. (B) Kaplan-Meier plot for fungal-
free survival: Log rank test p = 0.0194. The projected IFI-free
survival at 100 days was increased (50.1% vs. 25%; p = 0.0526).
Figure 2
Typical findings on computed tomography.
(A) Dense, well-circumscribed lesion with a halo (arrow) in the right
lower lobe in a patient with possible invasive fungal infection (IFI)
(B) Dense, well-circumscribed lesion in the left upper lobe (arrow)
in a patient with possible IFI (C and D) Dense lesion with an air-
crescent sign (arrows) in the right upper lobe in a patient with
proven IFI (mucorales spp.).
category, respectively. Intensive chemotherapy cycles con-
sisted of induction cycles I and II (138, 68%), conven-
tional consolidation (49, 24.1%), and relapse salvage ther-
apy (16, 7.9%). There was a statistically non-significant
trend to more salvage therapy cycles in the non-prophy-
laxis versus the prophylaxis group, with 13 (15.1%) and 3
(2.9%), respectively (p = 0.077). The number of chemo-
therapy cycles per patient excluding stem cell transplanta-
tion were one (n = 15, 17.1%), two (n = 37, 42%), three (n
= 30, 34.1%) or four (n = 6, 6.8%), respectively. The mean
aplasia time was significantly different in the prophylaxis
and the non-prophylaxis group (18.3 and 21 days, respect-
ively; p = 0.011). A total of 41 (20.2%) cycles were admin-
istered in the stem cell transplantation unit with statistic-
ally significantly more patients in the non-prophylaxis than
in the prophylaxis group, respectively (29.3%; and 9.6% p
= 0.012). A total of 35 patients (39.8%), of whom 15 in
the non-prophylaxis and 20 in the prophylaxis group, un-
derwent allogeneic hematopoietic stem cell transplantation
after the second (n = 21), the third (n = 6), and after salvage
therapy (n = 8), respectively.
Adherence to the prophylaxis scheme and screening
measures
In the non-prophylaxis group, posaconazole, levofloxacin,
and dexamethasone were given in a total of 1.9%, 2.2%
and 1% of all cycles, and in the prophylaxis group, in
81.7%, 69.5% and 90.5% of all evaluable cycles, respect-
ively (table 2). Posaconazole was given during 0.3 (0–17)
days/cycle in the non-prophylactic and 6.8 (0–30) days/
cycle in the prophylactic group. Posaconazole serum con-
centration was measured in 67.9% of all evaluable cycles in
the prophylaxis period, and resulted in a mean concentra-
tion of 0.38 mg/L (0–0.82). Galactomannan measurement
was performed during 13.1% of all cycles in the non-pro-
phylaxis and 3.8% in the prophylaxis period (p = 0.087). A
total of 91 low-dose chest CT exams were done in the non-
prophylaxis and 84 in the prophylaxis group (p = 0.07).
Local fungus surveillance programme:
We obtained environmental samples from three different
periods from the leukaemia ward. In March and April 2007
the median airborne Aspergillus fumigatus and Aspergillus
niger conidia levels were 2 to 24 colony-forming units
(CFUs) and 0 to 6 CFUs per cubic meter, respectively. The
same fungi were measured in March 2010 with 2 to 18
CFUs, and 2 to 4 CFUs, and in December 2010 with 0 to 4
CFUs, and 2 to 32 CFUs per cubic meter, respectively.
Fungal infections
IFI were significantly less common in the prophylaxis
group after the first chemotherapy cycle (13 (33.3%) vs.
25 (65.8%); p = 0.0088), as well as after the last chemo-
therapy cycle (21 (53.9%) vs. 32 (88.9%); p = 0.0021) (fig.
1A). The absolute risk reduction for IFI was 35% in the
prophylaxis group. The total days of anti-fungal medica-
tion (prophylaxis and therapy combined) per cycle did not
differ between the two groups (table 2). The Kaplan-Meier
plot shows a higher fungal-free survival in the prophylaxis
group (log rank test p = 0.0194) (fig. 1B). The majority of
IFI were classified as possible according the EORTC/MSG
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2008 criteria. Most IFI were pulmonary, and in most cases
the fungus type was not identified (table 3)
Bacterial infections
The incidence of chemotherapy cycles, that were complic-
ated by bacteraemia was 34.6% during the prophylaxis
period and 32.3% in the non-prophylaxis period (p = 0.8)
and the total number of positive blood cultures were 50 and
43, respectively (table 4). There was a statistically non-sig-
nificant trend to more gram-negative infections in the non-
prophylaxis-group (42% vs. 14%; p = 0.073) and to more
gram-positive infections in the prophylaxis group (86% vs.
58%; p = 0.092). Coagulase-negative Staphylococci and
Enterococcus faecium accounted for 70% of the positive
blood cultures during the prophylaxis period (table 4).
Secondary end points
Overall survival at 100 days and 2 years, mean ICU days,
the occurrence of neutropenic enterocolitis, as well as the
use of antiviral medication did not differ between the two
groups (table 5). However,fewer fever days (5.6 vs. 9.2; p =
0.00032) and less cytarabine skin toxicity (18.3% vs. 35%;
p = 0.025) were observed during the prophylaxis period.
Death and termination of therapy due to IFI
In the non-prophylaxis group four patients experienced
severe adverse events due to IFI: Patient one had
chemotherapy-resistant AML and died due to autoptically
confirmed septic emboli (mucorales spp.); patient two had
a relapse of the AML and possible pulmonary IFI, and died
of pulmonary haemorrhage; patient three had to stop AML
treatment after the second induction chemotherapy due to
possible pulmonary IFI; patient four had chemotherapy-
resistant AML and had to stop AML treatment after the
second induction chemotherapy due to probable pulmonary
IFI. In the prophylaxis group three patients experienced
severe adverse events due to IFI: Patient one had very poor-
risk AML and died of clinically and radiologically dia-
gnosed septic emboli, possibly related to mucorales (no
autopsy was performed); patient two had a relapse of the
AML after stem cell transplantation and died of autoptic-
ally confirmed pulmonary IFI with aspergillus spp; patient
three had chemotherapy-resistant AML and died of autop-
tically confirmed disseminated infection with mucorales
spp. and aspergillus spp (table 3).
Multivariate analysis
Posaconazole prophylaxis remained significantly associ-
ated with a lower occurrence of IFI when controlled for po-
tential confounders, such as duration of neutropenia, treat-
ment in the stem cell transplantation unit, and occurrence
of neutropenic enterocolitis (table 6). On average, the
patient-specific odds for occurrence of IFI are reduced by
a factor of 0.092 in the prophylaxis group compared to the
non-prophylaxis group (95%-CI [0.03, 0.31], p <0.0001).
Patient-specific odds for occurrence of IFI are also signi-
ficantly reduced for patients treated in the stem cell trans-
plantation unit when compared to the regular leukaemia
ward (OR = 0.174, 95%-CI [0.04, 0.70], p = 0.014).
Discussion
This real-world study aimed at investigating the effect of a
newly introduced combined anti-infective prophylaxis with
posaconazole and levofloxacin in patients undergoing in-
tensive chemotherapy for AML, APL and MDS. The study
demonstrated a positive effect of prophylaxis on the occur-
rence of invasive fungal infections (IFI), but no effect with
respect to bacteraemias.
The data on the efficacy of posaconazole in the prophylaxis
setting is in line with prior reports, however the net benefit
is surprisingly high, with a number-needed to treat of less
than three patients to prevent one ‘possible’ IFI [6, 11].
As we had anticipated, the rate of IFI in our institution
was higher, when compared to other published data: More
than 80% of patients without antifungal prophylaxis de-
veloped ‘possible’, ‘probable’ or ‘proven’ IFI at the end
of induction and consolidation chemotherapy, compared to
5–51.7% in prior studies [3, 6, 8]. However, a combined
endpoint of mortality and termination of the therapy due
to IFI in our institution was lower than 10% in both our
treatment groups, which is considerably less than what
would be expected from the literature, where a mortality
rate between 27% and >50% depending on the type and
the site of the fungus is reported with a downward trend in
the more recent publications [22–24]. Several factors might
have contributed to this favourable outcome. (1) our empir-
ical approach to guide antifungal treatment as well as early
detection of small lesions in the CT might be an effect-
ive clinical strategy, (2) the inclusion of possible IFI could
have led to over-diagnosis of IFI, and might therefore not
reflect the true outcome of IFI, (3) the choice of the em-
pirical and salvage regimen (amphotericin B dexocholate
as a 24h continuous infusion) might be very effective, and
(4) todays anti-fungals are known to be more effective than
older agents. The overall survival at 2 years was around
60% in both our treatment groups which is certainly in line
or better with what could be expected from the literature
[25].
The following factors might explain the relatively high pre-
valence of IFI as reported in our study: Most importantly,
the inclusion of ‘possible’ IFI in this analysis has most
probably led to over-diagnosis of IFI, as ‘possible’ IFI were
almost exclusively diagnosed based on a patient criterion
(prolonged neutropenia) and on the computed tomography
(CT) findings (fig. 3). CT scans were usually triggered by
persistent fever >48 to 72 hours despite broad-spectrum an-
tibiotics and false-positive results can occur. In this context
it is important to note, that there was not a significant dif-
ference between the numbers of CT scans performed in our
two treatment groups. Secondly, our data suggest that in-
frastructural characteristics might play a role, as there were
statistically less IFI in patients treated in the transplantation
ward, which is equipped with high efficiency particulate
air filtration and positive air pressure ventilation. Air filtra-
tion and positive pressure ventilation are known to provide
a higher degree of protection against IFI [26]. However,
and in contrast to what might be expected, even though
significantly more patients in the non-prophylaxis group
were treated in the stem cell transplantation ward, still the
pharmacological approach to prophylaxis led to a statistic-
Original article Swiss Med Wkly. 2014;144:w13985
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ally significant reduction of IFI in the prophylaxis group.
Thirdly, local differences such as the climate and building
activities are known to have an impact on the incidence of
IFI and might in part explain some of the reported differen-
ces [27]. Our surveillance data on airborne CFU are in line
with what could be expected from the literature [28–30].
However, measurement of airborne CFU is not very well
standardised and studies are therefore difficult to compare.
Despite the possible over-diagnosis of IFI in our real-
world-analysis, we decided to include all ‘possible’ IFI
as they represent an important and critical everyday prob-
lem for physicians caring for AML patients under intensive
chemotherapy. The diagnosis of ‘probable’ or ‘proven’ in-
vasive fungal infections remains notoriously difficult and
the yield of even an extensive diagnostic work-up includ-
ing biopsies and bronchoalveolar lavage is limited.
However, given the high morbidity and mortality of IFI we
Table 1: Patients baseline characteristics.
Non-prophylaxis Prophylaxis p-value
Number of patients 43 45
Mean age (years) 49.8 53.5
Male gender (%) 22 (51.2) 23 (51.1)
WHO diagnosis (%)
NOS
t(8;21)
inv16; t(16;16)
mutated NPM1
mutated CEBPA
t(9;11)
t(6;9)
inv3
tAML
AML MRC
RAEB2
APL
12 (27.9)
4 (9.3)
2 (4.7)
6 (13.9)
0 (0)
1 (2.3)
0 (0)
1 (2.3)
1 (2.3)
12 (27.9)
1 (2.3)
3 (7)
19 (42.2)
3 (6.7)
2 (4.4)
7 (15.6)
1 (2.2)
0 (0)
1 (2.2)
1 (2.2)
1 (2.2)
6 (13.3)
0 (0)
4 (8.9)
SAKK/HOVON 102 risk stratification (%)
Non applicable
Good risk
Intermediate risk
Poor risk
Very poor risk
4 (9.3)
14 (32.6)
8 (18.6)
11 (25.6)
6 (14)
4 (8.9)
16 (35.6)
4 (8.9)
17 (37.8)
4 (8.9)
Number of chemotherapy cycles 99 104
Chemotherapy cycles per patient (%)
1
2
3
4
8 (18.6)
17 (39.5)
15 (34.9)
3 (7)
7 (15.6)
20 (44.4)
15 (33.3)
3 (6.7)
Cytarabine cycles (%)
No cytarabine
Standard-dose cytarabine
Intermediate/high-dose cytarabine
16 (16.2)
40 (40.4)
43 (43.6)
22 (21.2)
43 (41.4)
39 (37.4)
Chemotherapy cycles (%)
Induction cycles I and II
Conventional consolidation
Salvage
61 (61.6)
25 (25.3)
13 (13.1)
77 (74)
24 (23.1)
3 (2.9)
0.077a
Chemotherapy cycles in transplantation ward (%) 29 (29.3) 10 (9.6) 0.012b
Aplasia duration in days per cycle$ 21 (10) 18.3 (8.8) 0.011c
$Mean (Standard deviation); aLogistic GEE reinduction vs. other; bLogistic GEE; normal vs. tpl ward; cPoisson GEE
Table 2: Adherence to anti-bacterial and anti-fungal prophylaxis, duration of anti-fungal prophylaxis/medication, IFI screening measures, and
posaconazole serum concentrations.
Non- prophylaxis Prophylaxis p-value
Chemotherapy cycles with (%)
posaconazole prophylaxis
levofloxacin prophylaxis
dexamethasone
1.9
2.2
1
81.7
69.5
90.5
Anti-fungal medication days per cycle$
Posaconazole prophylaxis
Total antifungal medication
0.3 (0–17)
25.3 (20.5)
6.8 (0–30)
20.3 (9.4) 0.066a
Galactomannan measurement per cycle (%)
None
any
86 (86.9)
13 (13.1)
100 (96.2)
4 (3.8)
0.087a
Chemotherapy cycles with CT scans (%) 91 (91.1) 84 (80) 0.07a
Posaconazole serum concentration (mg/L)$ NA 0.38 (0–0.82)
$Mean (min-max); aLogistic GEE at least one measurement/scan vs. none
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would not withhold antifungal treatment in a persistently
febrile neutropenic patient on broad-spectrum antibiotics
with a computed tomography scan compatible with an IFI
despite negative galactomannan measurement and a neg-
ative bronchoalveolar lavage. This is why we strongly be-
lieve that ‘possible’ IFI are a real-world problem and that
‘possible’ IFI have an impact on further patient manage-
ment as they tend to occur early in the course of the dis-
Table 3: Invasive fungal infections: Severe complications, probability according to EORTC/MSG 2008, site and fungus type.
No prophylaxis Prophylaxis p-value
Death or termination of therapy due to IFD (%) 4 (9.3) 3 (6.7) 0.79c
Fungal infection probability
according EORTC/MSG 2008
Possible
Probable
Proven
30
1
1
18
1
2
Fungal infection site Lung
Sinus
Hepatosplenic
30
1
1
19
0
2
Fungus type Unknown
Aspergillus
spp
Candida
glabrata
Candida
albicans
Mucorales
29
1
NA
1
1
17
2
1
NA
1
cLogistic GEE yes vs. no
Table 4: Duration of antibacterial prophylaxis/medication, incidence of bacteraemia and bacterial strains.
Non- prophylaxis Prophylaxis p-value
Anti-bacterial medication days per cycle$
levofloxacin prophylaxis
total anti-bacterial medication
0.2 (1.1)
23.6 (17.8)
10.3 (37.4)
28.7 (36.6) 0.31a
Chemotherapy cycles with bacteraemia (%) 32 (32.3) 36 (34.6) 0.8a
Positive blood cultures (%) 50 (100) 43 (100) 0.59a
Gram positive bacteria
Staphylococcus, coagulase-negative
Staphylococcus aureus
Staphylococcus haemolyticus
Enterococcus faecium
Enterococcus faecalis
Streptococcus pneumoniae
Streptococcus mitis
Streptococcus salivarius
Bacillus sp
Corynebacteria
29 (58)
9 (18)
–
1 (2)
8 (16)
1 (2)
–
5 (10)
2 (4)
1 (2)
2 (4)
37 (86)
16 (37)
1 (2)
1 (2)
14 (33)
–
1 (2)
2 (5)
1 (2)
1 (2)
–
0.092a
Gram negative bacteria
Escherichia coli
Escherichia coli, ESBL
Burkholderia cepacea
Klebsiella oxytoca
Klebsiella pneumoniae
Pseudomonas aeruginosa
Enterobactercloacae
Acinetobacter baumanii
Serratia marescens
Morganella morganii
Sphingopyxi ssp
Fusobacterium nucleatum
21 (42)
4 (8)
–
–
3 (6)
2 (4)
3 (6)
4 (8)
1 (2)
2 (4)
1 (2)
1 (2)
–
6 (14)
3 (7)
2 (5)
1 (2)
–
–
–
–
–
–
–
–
1 (2)
0.073a
$Mean (Standard deviation); aPoisson GEE
Table 5: Secondary endpoints: Overall survival and complications.
Non-prophylaxis Prophylaxis p-value
Overall survival at day 100 88.4% 84.4% 0.35a
Overall survival at 2 years 58.1% 64.4% 0.64a
Fever days/therapy cycle$ 9.2 (8.0) 5.6 (5.1) 0.00032b
ICU days/therapy cycle$ 2.4 (13) 1.7 (5.2) 0.66b
Cytarabine skin toxicity (%)# 29 (35) 15 (18.3) 0.025c
Anti-viral medication (%)& 63 (62.6) 54 (51.9) 0.38c
Neutropenic enterocolitis (%)& 28 (28.3) 24 (23.1) 0.51c
$Mean (Standard deviation); aLogistic regression; bPoisson GEE; #percentage of cytarabine-containing therapy cycles; dLogistic GEE;
&percentage of all therapy cycles
Original article Swiss Med Wkly. 2014;144:w13985
Swiss Medical Weekly · PDF of the online version · www.smw.ch Page 7 of 11
ease and lead to prolonged antifungal treatment, especially
following allogeneic stem cell transplantation. Hence, con-
siderable treatment costs are being shifted to the outpatient
setting. Preventing rather than treating IFI can reduce long-
term antifungal treatment and preclude possible side effects
and interactions [31–33].
Also, the high prevalence of IFI might have added to the
efficacy of the prophylactic approach in our patient pop-
ulation. We like to stress, however, that reduction in IFI
was achieved even though (i) overall adherence to posa-
conazole prophylaxis was only 81.7%; (ii) mean days of
antifungal prophylaxis was no longer than 6.7 days cover-
ing only one third of the total aplasia time; (iii) mean posa-
conazole serum concentration was low (0.38 ug/ml); and
(iv) more cycles in the non-prophylaxis group were applied
in air-filtered rooms. Thus, the results rather underestimate
the effect, and longer treatment and higher serum concen-
trations might lead to even more favourable results [34].
In today’s tight budgetary environment, the cost effect-
iveness of a prophylactic or therapeutic intervention is a
relevant consideration. In our institution with a relatively
high incidence of ‘possible’ IFI and a net drug cost of €
130/day for posaconazole prophylaxis and € 120/day for
intravenous amphotericin B deoxycholate, the prophylact-
ic approach seems to be cost effective. ‘Prophylaxis’ (6.7
days of posaconazole and 13.5 days of amphotericinB per
therapy cycle) and ‘non-prophylaxis’ (0.2 days of posa-
conazole and 25.1 days of amphotericin B deoxycholate
per therapy cycle) resulted in a total drug expense of ap-
proximately € 2500 and € 3000, respectively. The relevance
of this might be even more pronounced if liposomal am-
photericine B (€ 1700/day for an 80 kg patient with a dose
of 4 mg/kg/day) or alternative i.v. antimycotic drugs are
used. This is in line with the findings from other groups [3,
6, 35].
In contrast to previously published studies, antibacterial
prophylaxis with levofloxacin did not seem to be beneficial
in our patient population as it did not lead to a significant
reduction of bacteraemia [2, 16]. The reduction of Gram-
negative bacteraemia in the levofloxacin-prophylaxis
group was counterbalanced by an increase in Gram-posit-
ive bacteraemia. Enterococcus faecium and coagulase-neg-
ative Staphylococci accounted for 70% of all blood-stream
infections in the levofloxacin prophylaxis group. However,
the study groups might have been too small and the adher-
ence to levofloxacin in the prophylaxis group too low to
show a statistically significant difference.
Regarding the secondary endpoints, no difference in the
100 day overall survival was observed between the non-
prophylaxis and the prophylaxis group. Fever-days were
reduced significantly during the prophylaxis period and
cytarabine-induced skin toxicity was significantly less
common in the prophylaxis group, the latter being most
likely a consequence of adding dexamethasone to the pro-
phylaxis scheme.
There are some limitations to the current study: Firstly, the
retrospective design. Secondly, the two patient groups were
not perfectly matched regarding the aplasia duration and
the treatment in a ward with air filtration, which might in-
fluence the final results. However, the possible biases were
distributed in a counterbalanced way: (i) more patients dur-
ing the non-prophylaxis period received treatment in the
modern stem cell transplantation unit, a factor that was
associated with a lower incidence if IFI in the multivari-
ate analysis. (ii) The duration of aplasia was longer in the
non-prophylaxis group, and even though the duration was
not significantly associated with the occurrence of IFI in
our study, the duration of severe neutropenia is generally
known as a risk factor to favour infections [22].
Conclusions
We conclude that in our institution, which likely reflects
many hospital settings, posaconazole prophylaxis is highly
efficient in reducing possible invasive fungal infections,
with a number-needed to treat to prevent one IFI of only
3, and it is cost-efficient, while a clinically relevant benefit
of the anti-bacterial prophylaxis with levofloxacin was not
observed.
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Table 6: Multivariate analysis. Impact of posaconazole prophylaxis, aplasia duration, neutropenic enterocolitis and the infrastructure on the
occurrence of IFI.
Odds ratio (OR) 95% confidence interval for OR p-value
Posaconazole prophylaxis 0.092 [0.03, 0.31] 0.0001
Duration of Aplasia 1.071 [0.99, 1.16] 0.079
Neutropenic enterocolitis 1.016 [0.37, 2.81] 0.98
Transplantation ward 0.174 [0.04, 0.70] 0.014
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Figures (large format)
Figure 1
Invasive fungal infections and fungal-free survival.
(A) Patients with invasive fungal infection (IFI) after first cycle (non-prophylaxis 65.8% vs. prophylaxis 33.3%; p = 0.0088) and after the last cycle
of chemotherapy (non-prophylaxis 88.9% vs. prophylaxis 53.9%; p = 0.0032), respectively. (B) Kaplan-Meier plot for fungal-free survival: Log
rank test p = 0.0194. The projected IFI-free survival at 100 days was increased (50.1% vs. 25%; p = 0.0526).
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Figure 2
Typical findings on computed tomography.
(A) Dense, well-circumscribed lesion with a halo (arrow) in the right lower lobe in a patient with possible invasive fungal infection (IFI) (B) Dense,
well-circumscribed lesion in the left upper lobe (arrow) in a patient with possible IFI (C and D) Dense lesion with an air-crescent sign (arrows) in
the right upper lobe in a patient with proven IFI (mucorales spp.).
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